Breast Cancer Brachytherapy Benefits Still Unclear

Various types of APBI recurrence (external beam radiation, intraoperative radiotherapy, brachytherapy using multiple interstitial catheters, or intracavitary brachytherapy using a balloon catheter) deliver radiation to breast tissue at the highest risk of recurrence. Benefits of these techniques include decreased treatment time and less radiation to uninvolved portions of the breast and normal tissues.

Disadvantages of APBI include the potential that tumor cells in a different part of the breast will remain untreated, which could lead to increased local recurrence. Because of the potential limitations of APBI, in 2009 the American Society for Radiation Oncology (ASTRO; Fairfax, VA, USA) convened a task force of breast cancer experts to develop criteria for use of APBI off-protocol. They proposed three groups of APBI appropriateness: suitable, cautionary and unsuitable, based on patient characteristics and clinical factors.

Because of the growing popularity of APBIb specifically, Jona Hattangadi, MD, from the department of radiation oncology at the Brigham and Women’s Hospital and Harvard Medical School (both based in Boston, MA, USA) and colleagues performed a retrospective analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database of women who had received either APBIb or WBI between 2000 and 2007. In line with ASTRO guidelines, the researchers classified the 138,815 women as “suitable,” “cautionary,” or “unsuitable” for APBIb.

The investigators revealed that 3,576 of the 138,815 patients had received APBIb: 32% of whom would have been considered suitable, 29.6% cautionary, and 36.2% unsuitable. The overall use of APBIb increased from 0.4% in 2000 to 6.6% in 2007. There was a broad range of utilization patterns across the United States with specific geographic regions having higher APBIb use in spite of other patient and clinical factors. There were also considerable racial and ethnic discrepancies with respect to APBIb use. White women were more apt to get this treatment than black women among cautionary or unsuitable patients; and women living in cities were more likely to get it than those in rural areas even though it would potentially provide greater convenience for the rural women.
The authors concluded that, “the wide disparity in use of APBIb suggests that unwarranted variation--practice variation not explained by illness, patient preference, or evidence-based medicine--may be present. Future studies of APBIb use will help elucidate whether patterns change as [the ASTRO guidelines] diffuse into practice and whether the regional and temporal changes in APBIb cost, reimbursement, and insurance coverage affect utilization.”

In an accompanying editorial in the same issue, Simona F. Shaitelman, MD, from the department of radiation oncology at the University of Texas M.D. Anderson Cancer Center (Houston, USA), noted that it is encouraging that the authors discovered the fastest increase in utilization among patients classified as suitable, even if most of patients undergoing APBIb in their study were not classified as suitable. Dr. Shaitelman also commented on the authors’ suggestion that financial interests that might be fueling usage and noted that reimbursement was decreased for the procedure after the end of the period of the study. She wrote, “Moving forward, it will be useful to analyze more recent trends in the use of APBI and to document whether such changes in financial remuneration are indeed associated with the delivery of APBI.”

Dr. Shaitelman concluded that more research of the effectiveness of APBI is needed. “Although population based studies allow us to reflect on changes in patterns of practice, we are still left eagerly awaiting the results of large randomized trials that compare patients outcomes with WBI vs APBI.”

Related Links:
Brigham and Women’s Hospital
M.D. Anderson Cancer Center